Discovery of silyl proline containing HCV NS5A inhibitors with pan-genotype activity: SAR development
Authors:
- 1 March 2016
- journal article
- Published by Elsevier in Bioorganic & Medicinal Chemistry Letters
- Vol. 26 (5) , 1475-1479
Abstract
No abstract availableKeywords
This publication has 18 references indexed in Scilit:
- NS5A inhibitors in the treatment of hepatitis CJournal of Hepatology, 2013
- HCV NS5A Inhibitors in DevelopmentClinics in Liver Disease, 2013
- New Merck and Vertex drugs raise standard of care in hepatitis CNature Biotechnology, 2011
- Evolving epidemiology of hepatitis C virusClinical Microbiology and Infection, 2011
- Multiple ascending dose study of BMS-790052, a nonstructural protein 5A replication complex inhibitor, in patients infected with hepatitis C virus genotype 1Hepatology, 2010
- Advances in nucleoside monophosphate prodrugs as anti-HCV agentsAntiviral Therapy, 2010
- Chemical genetics strategy identifies an HCV NS5A inhibitor with a potent clinical effectNature, 2010
- HCV drug discovery aimed at viral eradicationJournal of Viral Hepatitis, 2010
- Ser2194 Is a Highly Conserved Major Phosphorylation Site of the Hepatitis C Virus Nonstructural Protein NS5AVirology, 2000
- Hepatitis C Virus NS5A Protein Is Phosphorylated by Casein Kinase IIBiochemical and Biophysical Research Communications, 1999